Summary & Overview
HCPCS Level II J7313: Fluocinolone Acetonide (Iluvien) Intravitreal Implant, 0.01 mg
HCPCS Level II code J7313 identifies the intravitreal implant of fluocinolone acetonide (Iluvien) 0.01 mg, a sustained-release corticosteroid device used in ophthalmic care. The code captures a drug-device insertion procedure with implications for specialty ophthalmology billing and outpatient infusion/device supply tables. Nationally, use of intravitreal steroid implants is significant for managing chronic retinal inflammatory and edematous conditions where sustained intraocular corticosteroid delivery can reduce treatment burden.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the product, the common site-of-service settings for billing, and the payer landscape addressed in the full publication. The report details reimbursement and coverage benchmarking, common billing and coding considerations for specialty drug-device implants, and relevant policy updates affecting outpatient ophthalmic therapeutics.
The publication is intended to help revenue cycle, coding professionals, and clinical administrators understand coding classification, payer coverage patterns, and operational factors tied to intravitreal implant billing. Data limitations where applicable are noted as "Data not available in the input."
Billing Code Overview
HCPCS Level II code J7313 represents an intravitreal implant containing fluocinolone acetonide (Iluvien) at a dose of 0.01 mg delivered via injection. This product is an extended-release corticosteroid device intended for intraocular use to provide sustained corticosteroid therapy.
Service type: Intravitreal injection / implant placement
Typical site of service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of chronic non-infectious posterior uveitis and recurrent macular edema presents to a retina clinic for long-term intravitreal steroid therapy. The retina specialist evaluates the patient in clinic, documents visual acuity, intraocular pressure, anterior and posterior segment exam, and reviews prior treatments including anti-VEGF injections and periocular steroids. After informed consent and verification of indications, the patient is scheduled for an in-office intravitreal placement of a fluocinolone acetonide intravitreal implant (J7313, Iluvien 0.01 mg). The typical workflow includes pre-procedure counseling, topical anesthesia and antisepsis, sterile implant delivery to the vitreous cavity, immediate post-procedure intraocular pressure check, and scheduling of follow-up visits to monitor intraocular pressure and response. The service is most commonly performed in an ophthalmology practice or ambulatory surgical center with staff trained in intravitreal procedures. Billing uses the HCPCS Level II code J7313 for the implant medication; facility and procedural CPT codes and appropriate modifiers are appended per payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default billing | Use when no special circumstances apply to the service billing. |